Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Melanoma 15Neoplasm Metastasis 11Ovarian Neoplasms 9Pancreatic Neoplasms 8Carcinoma, Non-Small-Cell Lung 8Stomach Neoplasms 6Skin Neoplasms 6Leukemia, Myeloid, Acute 6Colorectal Neoplasms 6Carcinoma, Renal Cell 6Triple Negative Breast Neoplasms 4Gastrointestinal Neoplasms 4Breast Neoplasms 4Vulvar Neoplasms 3Uterine Cervical Neoplasms 3Urogenital Neoplasms 3Rectal Neoplasms 3Neuroblastoma 3Myelodysplastic Syndromes 3Multiple Myeloma 3Leukemia 3Colonic Neoplasms 3Vaginal Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Sarcoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Pleural Effusion, Malignant 2Penile Neoplasms 2Oropharyngeal Neoplasms 2Neoplasms 2

Interventions

durvalumab 13Bevacizumab 11Nivolumab 10tremelimumab 7pembrolizumab 6lenvatinib 6fludarabine 6Cyclophosphamide 6atezolizumab 4Radiosurgery 4Cisplatin 4toripalimab 3relatlimab 3Magnetic Resonance Imaging 3Ipilimumab 3Gemcitabine 3X-Rays 2Standard of Care 2Sorafenib 2Riluzole 2Radiotherapy 2Photons 2Patient Navigation 2Lidocaine 2Hepatectomy 2Dexamethasone 2Biopsy 2trastuzumab deruxtecan 1tocilizumab 1tislelizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Liver Neoplasms × aldesleukin × 1 year × Clear all
NCT06690281 2025-09-11

A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal Malignancies

National Institutes of Health Clinical Center (CC)

Phase 2 Withdrawn
Gastrointestinal

Duodenal Neoplasms, Liver Neoplasms, Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡